

(FILE 'HOME' ENTERED AT 18:41:59 ON 24 APR 2006)

FILE 'REGISTRY' ENTERED AT 18:42:10 ON 24 APR 2006

L1 1427 S EFQQWSGK/SQSFP
L2 600 S NHVCSRLG/SQSFP
L3 6019 S IEETARKG/SQSFP
L4 8135 S NNATVEDE/SQSFP
L5 1017 S HSWKPKDL/SQSFP
L6 8524 S ETGERIVL/SQSFP
L7 1 S CIEETARKGC/SQSFP
L8 3 S CIEETAAGC/SQSFP
L9 1 S CEFQQWSGKC/SQSFP
L10 1 S CNHVCSRLGC/SQSFP
L11 1 S CNELHMKQHC/SQSFP
L12 1 S CNNATFEDGC/SQSFP
L13 6 S CNNATVEDEC/SQSFP
L14 1 S CDEKRGPNEC/SQSFP
L15 1696 S NELHMKQH/SQSFP
L16 69 S DEKRGPNEC/SQSFP
L17 1 S CHSWKPKDLC/SQSFP
L18 1 S CETGERIVLC/SQSFP
L19 2101 S NETTVREY/SQSFP
L20 1 S CNETTVREYC/SQSFP
L21 4727 S NNATFEDG/SQSFP
L22 7029 S VSEDIYDA/SQSFP
L23 1 S CVSEDIYDAC/SQSFP
~~L24 1 S CIEETARKGC/SQSP~~
L25 1 S CEFQQWSGKC/SQSP
L26 1 S CNHVCSRLGC/SQSP
L27 1 S CNELHMKQHC/SQSP
L28 1 S CNNATFEDGC/SQSP
L29 1 S CDEKRGPNEC/SQSP
L30 1 S CHSWKPKDLC/SQSP
L31 1 S CETGERIVLC/SQSP
L32 1 S CNETTVREYC/SQSP
L33 1 S CVSEDIYDAC/SQSP

L1-L6, L8, L13
L15, L16, L19
L21, L22

FILE 'HCAPLUS' ENTERED AT 18:53:17 ON 24 APR 2006

L34 488 S L1
L35 332 S L2
L36 2083 S L3
L37 2458 S L4
L38 456 S L5
L39 2258 S L6
L40 1 S L8
L41 3 S L13
L42 755 S L15
L43 24 S L16
L44 945 S L19
L45 1700 S L21
L46 1875 S L22
L47 5426 S L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
L48 3552 S L41 OR L42 OR L43 OR L44 OR L45 OR L46
L49 7584 S L47 OR L48
L50 261290 S MYELOID OR MYELOGENOUS OR AML OR LEUKOCYT? OR MARROW OR CML O
L51 332 S L49 AND L50
L52 363209 S MYELOID OR MYELOGENOUS OR AML OR MARROW OR GRANUL?
L53 94020 S MYELOID OR MYELOGENOUS OR AML OR MARROW
L54 140 S L49 AND L53
L55 47 S L54 AND AD<20020131
L56 73 S L54 AND PY<2003
L57 78 S L55 OR L56

(FILE 'HOME' ENTERED AT 18:41:59 ON 24 APR 2006)

FILE 'REGISTRY' ENTERED AT 18:42:10 ON 24 APR 2006

L1	1427	S	EFQQWSGK/SQSFP	623
L2	600	S	NHVCSRLG/SQSFP	624
L3	6019	S	IEETARKG/SQSFP	625
L4	8135	S	NNATVEDE/SQSFP	626
L5	1017	S	HSWKPKDL/SQSFP	627
L6	8524	S	ETGERIVL/SQSFP	628
L7	1	S	CIEETARKGC/SQSFP	
L8	3	S	CIEETAAGC/SQSFP	629
L9	1	S	CEFQQWSGKC/SQSFP	
L10	1	S	CNHVCSRLGC/SQSFP	
L11	1	S	CNELHMKQHC/SQSFP	
L12	1	S	CNNATFEDGC/SQSFP	
L13	6	S	CNNATVEDEC/SQSFP	630
L14	1	S	CDEKRGPNCE/SQSFP	
L15	1696	S	NELHMKQH/SQSFP	631
L16	69	S	DEKRGPNCE/SQSFP	632
L17	1	S	CHSWKPKDLC/SQSFP	
L18	1	S	CETGERIVLC/SQSFP	
L19	2101	S	NETTVREY/SQSFP	633
L20	1	S	CNETTVREYC/SQSFP	
L21	4727	S	NNATFEDG/SQSFP	634
L22	7029	S	VSEDIYDA/SQSFP	635
L23	1	S	CVSEDIYDAC/SQSFP	
L24	1	S	CIEETARKGC/SQSP	
L25	1	S	CEFQQWSGKC/SQSP	
L26	1	S	CNHVCSRLGC/SQSP	
L27	1	S	CNELHMKQHC/SQSP	
L28	1	S	CNNATFEDGC/SQSP	
L29	1	S	CDEKRGPNCE/SQSP	
L30	1	S	CHSWKPKDLC/SQSP	
L31	1	S	CETGERIVLC/SQSP	
L32	1	S	CNETTVREYC/SQSP	
L33	1	S	CVSEDIYDAC/SQSP	

FILE 'HCAPLUS' ENTERED AT 18:53:17 ON 24 APR 2006

L34	488	S	L1
L35	332	S	L2
L36	2083	S	L3
L37	2458	S	L4
L38	456	S	L5
L39	2258	S	L6
L40	1	S	L8
L41	3	S	L13
L42	755	S	L15
L43	24	S	L16
L44	945	S	L19
L45	1700	S	L21
L46	1875	S	L22
L47	5426	S	L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
L48	3552	S	L41 OR L42 OR L43 OR L44 OR L45 OR L46
L49	7584	S	L47 OR L48
L50	261290	S	MYELOID OR MYELOGENOUS OR AML OR LEUKOCYT? OR MARROW OR CML O
L51	332	S	L49 AND L50
L52	363209	S	MYELOID OR MYELOGENOUS OR AML OR MARROW OR GRANUL?
L53	94020	S	MYELOID OR MYELOGENOUS OR AML OR MARROW
L54	140	S	L49 AND L53
L55	47	S	L54 AND AD<20020131
L56	73	S	L54 AND PY<2003
L57	78	S	L55 OR L56
L58	0	S	L57 AND VERNET/AU

L59 0 S L57 AND VERNET/IN
L60 1 S L57 AND FCTR/TI

FILE 'REGISTRY' ENTERED AT 20:03:34 ON 24 APR 2006

L61 0 S L1 AND (505104-76-7)/RN
L62 0 S L2 AND (505104-76-7)/RN
L63 1 S L3 AND (505104-76-7)/RN
L64 1 S L3 AND (505104-78-9)/RN
L65 1 S L3 AND (505104-79-0)/RN
L66 0 S L4 AND (505104-79-0)/RN
L67 0 S L5 AND (505104-79-0)/RN
L68 0 S L6 AND (505104-79-0)/RN
L69 0 S L8 AND (505104-79-0)/RN
L70 0 S L13 AND (505104-79-0)/RN
L71 0 S L15 AND (505104-79-0)/RN
L72 0 S L16 AND (505104-79-0)/RN
L73 0 S L19 AND (505104-79-0)/RN
L74 0 S L21 AND (505104-79-0)/RN
L75 0 S L22 AND (505104-79-0)/RN
L76 0 S L1 AND (441408-43-1)/RN
L77 0 S L2 AND (441408-43-1)/RN
L78 0 S L3 AND (441408-43-1)/RN
L79 0 S L4 AND (441408-43-1)/RN
L80 0 S L5 AND (441408-43-1)/RN
L81 0 S L6 AND (441408-43-1)/RN
L82 0 S L8 AND (441408-43-1)/RN
L83 0 S L13 AND (441408-43-1)/RN
L84 1 S L15 AND (441408-43-1)/RN
L85 0 S L1 AND (404559-13-3)/RN
L86 0 S L2 AND (404559-13-3)/RN
L87 0 S L3 AND (404559-13-3)/RN
L88 1 S L4 AND (404559-13-3)/RN
L89 0 S L5 AND (404559-13-3)/RN
L90 0 S L6 AND (404559-13-3)/RN
L91 0 S L8 AND (404559-13-3)/RN
L92 0 S L13 AND (404559-13-3)/RN
L93 0 S L15 AND (404559-13-3)/RN
L94 0 S L16 AND (404559-13-3)/RN
L95 0 S L19 AND (404559-13-3)/RN
L96 0 S L22 AND (404559-13-3)/RN
L97 0 S L21 AND (404559-13-3)/RN
L98 0 S L1 AND (403561-79-5)/RN
L99 0 S L2 AND (403561-79-5)/RN
L100 0 S L3 AND (403561-79-5)/RN
L101 0 S L4 AND (403561-79-5)/RN
L102 0 S L5 AND (403561-79-5)/RN
L103 0 S L6 AND (403561-79-5)/RN
L104 0 S L8 AND (403561-79-5)/RN
L105 0 S L13 AND (403561-79-5)/RN
L106 0 S L15 AND (403561-79-5)/RN
L107 0 S L16 AND (403561-79-5)/RN
L108 1 S L19 AND (403561-79-5)/RN
L109 0 S L1 AND (357361)/RN
L110 0 S L2 AND (357361)/RN
L111 0 S L3 AND (357361)/RN
L112 0 S L4 AND (357361)/RN
L113 0 S L5 AND (357361)/RN
L114 0 S L6 AND (357361)/RN
L115 0 S L8 AND (357361)/RN
L116 0 S L13 AND (357361)/RN
L117 0 S L15 AND (357361)/RN
L118 0 S L16 AND (357361)/RN
L119 0 S L19 AND (357361)/RN

L120	0 S L21 AND (357361)/RN
L121	0 S L22 AND (357361)/RN
L122	0 S L1 AND (357361-72-9)/RN
L123	0 S L2 AND (357361-72-9)/RN
L124	1 S L3 AND (357361-72-9)/RN
L125	0 S L4 AND (357361-72-9)/RN
L126	0 S L5 AND (357361-72-9)/RN
L127	0 S L6 AND (357361-72-9)/RN
L128	0 S L8 AND (357361-72-9)/RN
L129	0 S L13 AND (357361-72-9)/RN
L130	0 S L15 AND (357361-72-9)/RN
L131	0 S L16 AND (357361-72-9)/RN
L132	0 S L19 AND (357361-72-9)/RN
L133	0 S L21 AND (357361-72-9)/RN
L134	0 S L22 AND (357361-72-9)/RN
L135	0 S L1 AND (358804-92-9)/RN
L136	0 S L2 AND (358804-92-9)/RN
L137	0 S L3 AND (358804-92-9)/RN
L138	0 S L4 AND (358804-92-9)/RN
L139	0 S L5 AND (358804-92-9)/RN
L140	0 S L6 AND (358804-92-9)/RN
L141	0 S L8 AND (358804-92-9)/RN
L142	0 S L15 AND (358804-92-9)/RN
L143	0 S L16 AND (358804-92-9)/RN
L144	0 S L19 AND (358804-92-9)/RN
L145	1 S L21 AND (358804-92-9)/RN
L146	0 S L22 AND (358804-92-9)/RN
L147	0 S L1 AND (310907-27-8)/RN
L148	0 S L2 AND (310907-27-8)/RN
L149	1 S L3 AND (310907-27-8)/RN
L150	0 S L4 AND (310907-27-8)/RN
L151	0 S L5 AND (310907-27-8)/RN
L152	0 S L6 AND (310907-27-8)/RN
L153	0 S L8 AND (310907-27-8)/RN
L154	0 S L15 AND (310907-27-8)/RN
L155	0 S L16 AND (310907-27-8)/RN
L156	0 S L19 AND (310907-27-8)/RN
L157	0 S L21 AND (310907-27-8)/RN
L158	0 S L22 AND (310907-27-8)/RN
L159	0 S L1 AND (294682-28-3)/RN
L160	0 S L2 AND (294682-28-3)/RN
L161	0 S L3 AND (294682-28-3)/RN
L162	0 S L4 AND (294682-28-3)/RN
L163	0 S L5 AND (294682-28-3)/RN
L164	1 S L6 AND (294682-28-3)/RN
L165	0 S L8 AND (294682-28-3)/RN
L166	0 S L15 AND (294682-28-3)/RN
L167	0 S L16 AND (294682-28-3)/RN
L168	0 S L19 AND (294682-28-3)/RN
L169	0 S L21 AND (294682-28-3)/RN
L170	0 S L22 AND (294682-28-3)/RN
L171	0 S L1 AND (275828-97-2)/RN
L172	0 S L2 AND (275828-97-2)/RN
L173	0 S L3 AND (275828-97-2)/RN
L174	1 S L4 AND (275828-97-2)/RN
L175	0 S L5 AND (275828-97-2)/RN
L176	0 S L6 AND (275828-97-2)/RN
L177	0 S L7 AND (275828-97-2)/RN
L178	0 S L8 AND (275828-97-2)/RN
L179	0 S L15 AND (275828-97-2)/RN
L180	0 S L16 AND (275828-97-2)/RN
L181	0 S L19 AND (275828-97-2)/RN
L182	0 S L21 AND (275828-97-2)/RN

L183	0 S L22 AND (275828-97-2)/RN
L184	0 S L1 AND (220134-97-4)/RN
L185	0 S L2 AND (220134-97-4)/RN
L186	0 S L3 AND (220134-97-4)/RN
L187	0 S L4 AND (220134-97-4)/RN
L188	0 S L5 AND (220134-97-4)/RN
L189	0 S L6 AND (220134-97-4)/RN
L190	0 S L8 AND (220134-97-4)/RN
L191	0 S L15 AND (220134-97-4)/RN
L192	0 S L16 AND (220134-97-4)/RN
L193	0 S L19 AND (220134-97-4)/RN
L194	0 S L121 AND (220134-97-4)/RN
L195	0 S L122 AND (220134-97-4)/RN
L196	0 S L1 AND (245673-98-7)/RN
L197	0 S L2 AND (245673-98-7)/RN
L198	0 S (245673-98-7)/RN AND L3
L199	0 S (245673-98-7)/RN AND L4
L200	0 S (245673-98-7)/RN AND L5
L201	0 S (245673-98-7)/RN AND L6
L202	0 S (245673-98-7)/RN AND L8
L203	0 S (245673-98-7)/RN AND L13
L204	0 S (245673-98-7)/RN AND L15
L205	0 S (245673-98-7)/RN AND L16
L206	0 S (245673-98-7)/RN AND L19
L207	1 S (245673-98-7)/RN AND L21
L208	0 S (245673-98-7)/RN AND L22
L209	0 S (212774-49-7)/RN AND L1
L210	0 S (212774-49-7)/RN AND L2
L211	0 S (212774-49-7)/RN AND L3
L212	0 S (212774-49-7)/RN AND L4
L213	0 S (212774-49-7)/RN AND L5
L214	1 S (212774-49-7)/RN AND L6
L215	0 S (212774-49-7)/RN AND L8
L216	0 S (212774-49-7)/RN AND L1
L217	0 S (212774-49-7)/RN AND L13
L218	0 S (212774-49-7)/RN AND L15
L219	0 S (212774-49-7)/RN AND L16
L220	0 S (212774-49-7)/RN AND L19
L221	0 S (212774-49-7)/RN AND L21
L222	0 S (212774-49-7)/RN AND L22
L223	0 S (208768-96-1)/RN AND L1
L224	0 S (208768-96-1)/RN AND L2
L225	0 S (208768-96-1)/RN AND L3
L226	0 S (208768-96-1)/RN AND L4
L227	0 S (208768-96-1)/RN AND L5
L228	0 S (208768-96-1)/RN AND L6
L229	0 S (208768-96-1)/RN AND L8
L230	0 S (208768-96-1)/RN AND L13
L231	0 S (208768-96-1)/RN AND L15
L232	0 S (208768-96-1)/RN AND L16
L233	0 S (208768-96-1)/RN AND L19
L234	1 S (208768-96-1)/RN AND L21
L235	0 S (208768-96-1)/RN AND L22
L236	0 S (203211-65-8)/RN AND L1
L237	0 S (203211-65-8)/RN AND L2
L238	0 S (203211-65-8)/RN AND L3
L239	1 S (203211-65-8)/RN AND L4
L240	0 S (203211-65-8)/RN AND L5
L241	0 S (203211-65-8)/RN AND L6
L242	0 S (203211-65-8)/RN AND L8
L243	0 S (203211-65-8)/RN AND L13
L244	0 S (203211-65-8)/RN AND L15
L245	0 S (203211-65-8)/RN AND L16

L246	0	S	(203211-65-8)/RN	AND	L19
L247	0	S	(203211-65-8)/RN	AND	L21
L248	0	S	(203211-65-8)/RN	AND	L22
L249	0	S	(194615-66-2)/RN	AND	L1
L250	0	S	(194615-66-2)/RN	AND	L2
L251	0	S	(194615-66-2)/RN	AND	L3
L252	1	S	(194615-66-2)/RN	AND	L4
L253	0	S	(194615-66-2)/RN	AND	L5
L254	0	S	(194615-66-2)/RN	AND	L6
L255	0	S	(194615-66-2)/RN	AND	L8
L256	0	S	(194615-66-2)/RN	AND	L13
L257	0	S	(194615-66-2)/RN	AND	L15
L258	0	S	(194615-66-2)/RN	AND	L16
L259	0	S	(194615-66-2)/RN	AND	L19
L260	0	S	(194615-66-2)/RN	AND	L21
L261	0	S	(194615-66-2)/RN	AND	L22
L262	0	S	(360804-23-5)/RN	AND	L1
L263	0	S	(360804-23-5)/RN	AND	L2
L264	1	S	(360804-23-5)/RN	AND	L3
L265	0	S	(360804-23-5)/RN	AND	L4
L266	0	S	(360804-23-5)/RN	AND	L5
L267	0	S	(360804-23-5)/RN	AND	L6
L268	0	S	(360804-23-5)/RN	AND	L8
L269	0	S	(360804-23-5)/RN	AND	L13
L270	0	S	(360804-23-5)/RN	AND	L15
L271	0	S	(360804-23-5)/RN	AND	L16
L272	0	S	(360804-23-5)/RN	AND	L19
L273	0	S	(360804-23-5)/RN	AND	L21
L274	0	S	(360804-23-5)/RN	AND	L22
L275	0	S	(339609-69-7)/RN	AND	L1
L276	0	S	(339609-69-7)/RN	AND	L2
L277	0	S	(339609-69-7)/RN	AND	L3
L278	0	S	(339609-69-7)/RN	AND	L4
L279	0	S	(339609-69-7)/RN	AND	L5
L280	0	S	(339609-69-7)/RN	AND	L6
L281	0	S	(339609-69-7)/RN	AND	L8
L282	0	S	(339609-69-7)/RN	AND	L13
L283	0	S	(339609-69-7)/RN	AND	L15
L284	0	S	(339609-69-7)/RN	AND	L16
L285	0	S	(339609-69-7)/RN	AND	L19
L286	0	S	(339609-69-7)/RN	AND	L21
L287	1	S	(339609-69-7)/RN	AND	L22
L288	0	S	(339609-72-2)/RN	AND	L1
L289	0	S	(339609-72-2)/RN	AND	L2
L290	0	S	(339609-72-2)/RN	AND	L3
L291	0	S	(339609-72-2)/RN	AND	L4
L292	0	S	(339609-72-2)/RN	AND	L5
L293	0	S	(339609-72-2)/RN	AND	L6
L294	0	S	(339609-72-2)/RN	AND	L8
L295	0	S	(339609-72-2)/RN	AND	L13
L296	0	S	(339609-72-2)/RN	AND	L15
L297	0	S	(339609-72-2)/RN	AND	L16
L298	0	S	(339609-72-2)/RN	AND	L19
L299	0	S	(339609-72-2)/RN	AND	L21
L300	1	S	(339609-72-2)/RN	AND	L22
L301	1	S	(339609-79-9)/RN	AND	L22
L302	1	S	(339609-80-2)/RN	AND	L22
L303	1	S	(339614-25-4)/RN	AND	L22
L304	1	S	(339614-26-5)/RN	AND	L22
L305	0	S	(372032-61-6)/RN	AND	L1
L306	0	S	(372032-61-6)/RN	AND	L2
L307	0	S	(372032-61-6)/RN	AND	L3
L308	0	S	(372032-61-6)/RN	AND	L4

L309	0 S (372032-61-6)/RN AND L5
L310	0 S (372032-61-6)/RN AND L6
L311	0 S (372032-61-6)/RN AND L8
L312	0 S (372032-61-6)/RN AND L13
L313	0 S (372032-61-6)/RN AND L15
L314	0 S (372032-61-6)/RN AND L16
L315	1 S (372032-61-6)/RN AND L19
L316	0 S L19 AND (372032-98-9)/RN
L317	0 S L19 AND (372035-37-5)/RN
L318	0 S L21 AND (372032-98-9)/RN
L319	1 S L22 AND (372032-98-9)/RN
L320	0 S L21 AND (372035-37-5)/RN
L321	0 S L22 AND (372035-37-5)/RN
L322	0 S (372035-37-5)/RN AND L1
L323	0 S (372035-37-5)/RN AND L2
L324	0 S (372035-37-5)/RN AND L3
L325	0 S (372035-37-5)/RN AND L4
L326	0 S (372035-37-5)/RN AND L5
L327	1 S (372035-37-5)/RN AND L6
L328	0 S (372035-92-2)/RN AND L1
L329	0 S (372035-92-2)/RN AND L2
L330	0 S (372035-92-2)/RN AND L3
L331	0 S (372035-92-2)/RN AND L4
L332	0 S (372035-92-2)/RN AND L5
L333	1 S (372035-92-2)/RN AND L6
L334	0 S (372036-31-2)/RN AND L1
L335	0 S (372036-31-2)/RN AND L2
L336	0 S (372036-31-2)/RN AND L3
L337	0 S (372036-31-2)/RN AND L4
L338	0 S (372036-31-2)/RN AND L5
L339	0 S (372036-31-2)/RN AND L6
L340	0 S (372036-31-2)/RN AND L8
L341	0 S (372036-31-2)/RN AND L13
L342	0 S (372036-31-2)/RN AND L15
L343	0 S (372036-31-2)/RN AND L16
L344	1 S (372036-31-2)/RN AND L19
L345	0 S (372037-96-2)/RN AND L1
L346	0 S (372037-96-2)/RN AND L2
L347	0 S (372037-96-2)/RN AND L3
L348	0 S (372037-96-2)/RN AND L4
L349	0 S (372037-96-2)/RN AND L5
L350	0 S (372037-96-2)/RN AND L6
L351	0 S (372037-96-2)/RN AND L8
L352	0 S (372037-96-2)/RN AND L13
L353	0 S (372037-96-2)/RN AND L15
L354	0 S (372037-96-2)/RN AND L16
L355	0 S (372037-96-2)/RN AND L19
L356	1 S (372037-96-2)/RN AND L21
L357	0 S (372038-45-4)/RN AND L1
L358	0 S (372038-45-4)/RN AND L2
L359	1 S (372038-45-4)/RN AND L3
L360	0 S (372038-55-6)/RN AND L1
L361	0 S (372038-55-6)/RN AND L2
L362	0 S (372038-55-6)/RN AND L3
L363	0 S (372038-55-6)/RN AND L4
L364	0 S (372038-55-6)/RN AND L5
L365	1 S (372038-55-6)/RN AND L6
L366	0 S (372038-64-7)/RN AND L1
L367	0 S (372038-64-7)/RN AND L2
L368	0 S (372038-64-7)/RN AND L3
L369	1 S (372038-64-7)/RN AND L4
L370	0 S (372039-55-9)/RN AND L1
L371	0 S (372039-55-9)/RN AND L2

L372	1	S	(372039-55-9)/RN	AND	L3
L373	0	S	(372039-71-9)/RN	AND	L1
L374	0	S	(372039-71-9)/RN	AND	L2
L375	1	S	(372039-71-9)/RN	AND	L3
L376	0	S	(372040-47-6)/RN	AND	L1
L377	0	S	(372040-47-6)/RN	AND	L2
L378	0	S	(372040-47-6)/RN	AND	L3
L379	0	S	(372040-47-6)/RN	AND	L4
L380	0	S	(372040-47-6)/RN	AND	L5
L381	0	S	(372040-47-6)/RN	AND	L6
L382	0	S	(372040-47-6)/RN	AND	L8
L383	0	S	(372040-47-6)/RN	AND	L13
L384	0	S	(372040-47-6)/RN	AND	L15
L385	0	S	(372040-47-6)/RN	AND	L16
L386	0	S	(372040-47-6)/RN	AND	L19
L387	1	S	(372040-47-6)/RN	AND	L21
L388	0	S	(372041-34-4)/RN	AND	L1
L389	0	S	(372041-34-4)/RN	AND	L2
L390	1	S	(372041-34-4)/RN	AND	L3
L391	0	S	(372043-19-1)/RN	AND	L1
L392	0	S	(372043-19-1)/RN	AND	L2
L393	0	S	(372043-19-1)/RN	AND	L3
L394	0	S	(372043-19-1)/RN	AND	L4
L395	0	S	(372043-19-1)/RN	AND	L5
L396	1	S	(372043-19-1)/RN	AND	L6
L397	0	S	(372044-44-5)/RN	AND	L1
L398	0	S	(372044-44-5)/RN	AND	L2
L399	0	S	(372044-44-5)/RN	AND	L3
L400	0	S	(372044-44-5)/RN	AND	L4
L401	0	S	(372044-44-5)/RN	AND	L5
L402	1	S	(372044-44-5)/RN	AND	L6
L403	0	S	(372045-45-9)/RN	AND	L1
L404	0	S	(372045-45-9)/RN	AND	L2
L405	0	S	(372045-45-9)/RN	AND	L3
L406	0	S	(372045-45-9)/RN	AND	L4
L407	0	S	(372045-45-9)/RN	AND	L5
L408	0	S	(372045-45-9)/RN	AND	L6
L409	0	S	(372045-45-9)/RN	AND	L8
L410	0	S	(372045-45-9)/RN	AND	L13
L411	0	S	(372045-45-9)/RN	AND	L15
L412	0	S	(372045-45-9)/RN	AND	L16
L413	0	S	(372045-45-9)/RN	AND	L19
L414	1	S	(372045-45-9)/RN	AND	L21
L415	0	S	(372046-48-5)/RN	AND	L1
L416	0	S	(372046-48-5)/RN	AND	L2
L417	0	S	(372046-48-5)/RN	AND	L3
L418	0	S	(372046-48-5)/RN	AND	L4
L419	0	S	(372046-48-5)/RN	AND	L5
L420	1	S	(372046-48-5)/RN	AND	L6
L421	0	S	(372046-73-6)/RN	AND	L1
L422	0	S	(372046-73-6)/RN	AND	L2
L423	0	S	(372046-73-6)/RN	AND	L3
L424	1	S	(372046-73-6)/RN	AND	L4
L425	0	S	(372047-29-5)/RN	AND	L1
L426	0	S	(372047-29-5)/RN	AND	L2
L427	0	S	(372047-29-5)/RN	AND	L3
L428	0	S	(372047-29-5)/RN	AND	L4
L429	0	S	(372047-29-5)/RN	AND	L5
L430	1	S	(372047-29-5)/RN	AND	L6
L431	0	S	(372052-15-8)/RN	AND	L1
L432	0	S	(372052-15-8)/RN	AND	L2
L433	0	S	(372052-15-8)/RN	AND	L3
L434	0	S	(372052-15-8)/RN	AND	L4

L435	0 S (372052-15-8)/RN AND L5
L436	0 S (372052-15-8)/RN AND L6
L437	0 S (372052-15-8)/RN AND L8
L438	0 S (372052-15-8)/RN AND L13
L439	0 S (372052-15-8)/RN AND L15
L440	0 S (372052-15-8)/RN AND L16
L441	0 S (372052-15-8)/RN AND L19
L442	1 S (372052-15-8)/RN AND L21
L443	0 S (372052-75-0)/RN AND L1
L444	0 S (372052-75-0)/RN AND L2
L445	0 S (372052-75-0)/RN AND L3
L446	0 S (372052-75-0)/RN AND L4
L447	0 S (372052-75-0)/RN AND L5
L448	0 S (372052-75-0)/RN AND L6
L449	0 S (372052-75-0)/RN AND L8
L450	0 S (372052-75-0)/RN AND L13
L451	1 S (372052-75-0)/RN AND L15
L452	0 S (372053-99-1)/RN AND L1
L453	0 S (372053-99-1)/RN AND L2
L454	1 S (372053-99-1)/RN AND L3
L455	0 S (372056-50-3)/RN AND L1
L456	0 S (372056-50-3)/RN AND L2
L457	1 S (372056-50-3)/RN AND L3
L458	0 S (372058-05-4)/RN AND L1
L459	0 S (372058-05-4)/RN AND L2
L460	0 S (372058-05-4)/RN AND L3
L461	1 S (372058-05-4)/RN AND L4
L462	0 S (372058-89-4)/RN AND L1
L463	0 S (372058-89-4)/RN AND L2
L464	1 S (372058-89-4)/RN AND L3
L465	0 S (372060-52-1)/RN AND L1
L466	0 S (372060-52-1)/RN AND L2
L467	0 S (372060-52-1)/RN AND L3
L468	0 S (372060-52-1)/RN AND L4
L469	0 S (372060-52-1)/RN AND L5
L470	0 S (372060-52-1)/RN AND L6
L471	0 S (372060-52-1)/RN AND L8
L472	0 S (372060-52-1)/RN AND L13
L473	0 S (372060-52-1)/RN AND L115
L474	0 S (372060-52-1)/RN AND L15
L475	0 S (372060-52-1)/RN AND L16
L476	0 S (372060-52-1)/RN AND L19
L477	1 S (372060-52-1)/RN AND L21
L478	0 S (372060-72-5)/RN AND L1
L479	0 S (372060-72-5)/RN AND L2
L480	1 S (372060-72-5)/RN AND L3
L481	0 S (372062-39-0)/RN AND L1
L482	0 S (372062-39-0)/RN AND L2
L483	0 S (372062-39-0)/RN AND L3
L484	0 S (372062-39-0)/RN AND L4
L485	0 S (372062-39-0)/RN AND L5
L486	1 S (372062-39-0)/RN AND L6
L487	0 S (372064-72-7)/RN AND L1
L488	0 S (372064-72-7)/RN AND L2
L489	0 S (372064-72-7)/RN AND L3
L490	0 S (372064-72-7)/RN AND L4
L491	0 S (372064-72-7)/RN AND L5
L492	0 S (372064-72-7)/RN AND L6
L493	0 S (372064-72-7)/RN AND L8
L494	0 S (372064-72-7)/RN AND L13
L495	0 S (372064-72-7)/RN AND L15
L496	0 S (372064-72-7)/RN AND L16
L497	1 S (372064-72-7)/RN AND L19

L498	0	S	(372065-11-7)/RN	AND	L1
L499	0	S	(372065-11-7)/RN	AND	L2
L500	0	S	(372065-11-7)/RN	AND	L3
L501	1	S	(372065-11-7)/RN	AND	L4
L502	0	S	(372065-92-4)/RN	AND	L1
L503	0	S	(372065-92-4)/RN	AND	L2
L504	1	S	(372065-92-4)/RN	AND	L3
L505	0	S	(372067-88-4)/RN	AND	L1
L506	0	S	(372067-88-4)/RN	AND	L2
L507	0	S	(372067-88-4)/RN	AND	L3
L508	0	S	(372067-88-4)/RN	AND	L4
L509	0	S	(372067-88-4)/RN	AND	L5
L510	0	S	(372067-88-4)/RN	AND	L6
L511	0	S	(372067-88-4)/RN	AND	L8
L512	0	S	(372067-88-4)/RN	AND	L13
L513	0	S	(372067-88-4)/RN	AND	L15
L514	0	S	(372067-88-4)/RN	AND	L16
L515	0	S	(372067-88-4)/RN	AND	L19
L516	0	S	(372067-88-4)/RN	AND	L21
L517	1	S	(372067-88-4)/RN	AND	L22
L518	0	S	(372067-95-3)/RN	AND	L1
L519	0	S	(372067-95-3)/RN	AND	L2
L520	0	S	(372067-95-3)/RN	AND	L3
L521	0	S	(372067-95-3)/RN	AND	L4
L522	1	S	(372067-95-3)/RN	AND	L5
L523	0	S	(372068-15-0)/RN	AND	L1
L524	0	S	(372068-15-0)/RN	AND	L2
L525	0	S	(372068-15-0)/RN	AND	L3
L526	1	S	(372068-15-0)/RN	AND	L4
L527	0	S	(372068-73-0)/RN	AND	L1
L528	0	S	(372068-73-0)/RN	AND	L2
L529	0	S	(372068-73-0)/RN	AND	L3
L530	0	S	(372068-73-0)/RN	AND	L4
L531	0	S	(372068-73-0)/RN	AND	L5
L532	1	S	(372068-73-0)/RN	AND	L6
L533	0	S	(372070-81-0)/RN	AND	L1
L534	0	S	(372070-81-0)/RN	AND	L2
L535	0	S	(372070-81-0)/RN	AND	L3
L536	0	S	(372070-81-0)/RN	AND	L4
L537	0	S	(372070-81-0)/RN	AND	L5
L538	1	S	(372070-81-0)/RN	AND	L6
L539	1	S	(372071-05-1)/RN	AND	L1
L540	0	S	(372071-07-3)/RN	AND	L1
L541	0	S	(372071-07-3)/RN	AND	L2
L542	0	S	(372071-07-3)/RN	AND	L3
L543	0	S	(372071-07-3)/RN	AND	L4
L544	0	S	(372071-07-3)/RN	AND	L5
L545	0	S	(372071-07-3)/RN	AND	L6
L546	0	S	(372071-07-3)/RN	AND	L8
L547	0	S	(372071-07-3)/RN	AND	L13
L548	0	S	(372071-07-3)/RN	AND	L15
L549	0	S	(372071-07-3)/RN	AND	L16
L550	0	S	(372071-07-3)/RN	AND	L19
L551	0	S	(372071-07-3)/RN	AND	L21
L552	1	S	(372071-07-3)/RN	AND	L22
L553	0	S	(372071-11-9)/RN	AND	L1
L554	0	S	(372071-11-9)/RN	AND	L2
L555	0	S	(372071-11-9)/RN	AND	L3
L556	0	S	(372071-11-9)/RN	AND	L4
L557	0	S	(372071-11-9)/RN	AND	L5
L558	0	S	(372071-11-9)/RN	AND	L6
L559	0	S	(372071-11-9)/RN	AND	L8
L560	0	S	(372071-11-9)/RN	AND	L15

L561	0	S	(372071-11-9)/RN	AND	L13
L562	0	S	(372071-11-9)/RN	AND	L16
L563	0	S	(372071-11-9)/RN	AND	L19
L564	0	S	(372071-11-9)/RN	AND	L21
L565	1	S	(372071-11-9)/RN	AND	L22
L566	0	S	(372071-90-4)/RN	AND	L1
L567	0	S	(372071-90-4)/RN	AND	L2
L568	1	S	(372071-90-4)/RN	AND	L3
L569	0	S	(372071-95-9)/RN	AND	L1
L570	0	S	(372071-95-9)/RN	AND	L2
L571	0	S	(372071-95-9)/RN	AND	L3
L572	0	S	(372071-95-9)/RN	AND	L4
L573	0	S	(372071-95-9)/RN	AND	L5
L574	0	S	(372071-95-9)/RN	AND	L6
L575	0	S	(372071-95-9)/RN	AND	L8
L576	0	S	(372071-95-9)/RN	AND	L13
L577	0	S	(372071-95-9)/RN	AND	L15
L578	0	S	(372071-95-9)/RN	AND	L16
L579	0	S	(372071-95-9)/RN	AND	L19
L580	1	S	(372071-95-9)/RN	AND	L21
L581	0	S	(372072-3-5)/RN	AND	L1
L582	0	S	(372072-3-5)/RN	AND	L2
L583	0	S	(372072-3-5)/RN	AND	L3
L584	0	S	(372072-3-5)/RN	AND	L4
L585	0	S	(372072-3-5)/RN	AND	L5
L586	0	S	(372072-3-5)/RN	AND	L6
L587	0	S	(372072-3-5)/RN	AND	L7
L588	0	S	(372072-3-5)/RN	AND	L8
L589	0	S	(372072-3-5)/RN	AND	L13
L590	0	S	(372072-3-5)/RN	AND	L15
L591	0	S	(372072-3-5)/RN	AND	L16
L592	0	S	(372072-3-5)/RN	AND	L19
L593	0	S	(372072-30-5)/RN	AND	L1
L594	0	S	(372072-30-5)/RN	AND	L2
L595	0	S	(372072-30-5)/RN	AND	L3
L596	0	S	(372072-30-5)/RN	AND	L4
L597	1	S	(372072-30-5)/RN	AND	L5
L598	0	S	(372072-78-1)/RN	AND	L1
L599	0	S	(372072-78-1)/RN	AND	L2
L600	0	S	(372072-78-1)/RN	AND	L3
L601	0	S	(372072-78-1)/RN	AND	L4
L602	0	S	(372072-78-1)/RN	AND	L5
L603	1	S	(372072-78-1)/RN	AND	L6
L604	0	S	(372073-21-7)/RN	AND	L1
L605	0	S	(372073-21-7)/RN	AND	L2
L606	0	S	(372073-21-7)/RN	AND	L3
L607	0	S	(372073-21-7)/RN	AND	L4
L608	0	S	(372073-21-7)/RN	AND	L5
L609	0	S	(372073-21-7)/RN	AND	L6
L610	0	S	(372073-21-7)/RN	AND	L8
L611	0	S	(372073-21-7)/RN	AND	L13
L612	0	S	(372073-21-7)/RN	AND	L15
L613	0	S	(372073-21-7)/RN	AND	L16
L614	0	S	(372073-21-7)/RN	AND	L19
L615	0	S	(372073-21-7)/RN	AND	L21
L616	1	S	(372073-21-7)/RN	AND	L22
L617	0	S	(372488-87-4)/RN	AND	L1
L618	0	S	(372488-87-4)/RN	AND	L2
L619	0	S	(372488-87-4)/RN	AND	L3
L620	0	S	(372488-87-4)/RN	AND	L4
L621	0	S	(372488-87-4)/RN	AND	L5
L622	1	S	(372488-87-4)/RN	AND	L6

(FILE 'REGISTRY' ENTERED AT 20:03:34 ON 24 APR 2006)

L620	0 S (372488-87-4)/RN AND L4
L621	0 S (372488-87-4)/RN AND L5
L622	1 S (372488-87-4)/RN AND L6
L623	17 S L1 AND SQL<13
L624	2 S L2 AND SQL<13
L625	7 S L3 AND SQL<13
L626	6 S L4 AND SQL<13
L627	3 S L5 AND SQL<13
L628	4 S L6 AND SQL<13
L629	1 S L8 AND SQL<13
L630	1 S L13 AND SQL<13
L631	2 S L15 AND SQL<13
L632	2 S L16 AND SQL<13
L633	3 S L19 AND SQL<13
L634	7 S L21 AND SQL<13
L635	2 S L22 AND SQL<13

FILE 'HCAPLUS' ENTERED AT 21:51:13 ON 24 APR 2006

L636	2 S L623
L637	1 S L624
L638	5 S L625
L639	5 S L626
L640	1 S L631
L641	1 S L632
L642	2 S L633
L643	2 S L634
L644	1 S L635
L645	2 S L627
L646	3 S L628
L647	0 S L636 AND AD<20020131
L648	0 S L636 AND PY<2002
L649	0 S L637 AND AD<20020131
L650	0 S L637 AND PY<2002
L651	1 S L638 AND AD<20020131
L652	3 S L638 AND PY<2002
L653	3 S L651 OR L652
L654	3 S L639 AND AD<20020131
L655	2 S L639 AND PY<2002
L656	3 S L654 OR L655
L657	0 S L640 AND AD<20020131
L658	0 S L640 AND PY<2002
L659	0 S L641 AND AD<20020131
L660	0 S L641 AND PY<2002
L661	0 S L642 AND AD<20020131
L662	0 S L642 AND PY<2002
L663	0 S L643 AND AD<20020131
L664	0 S L643 AND PY<2002
L665	0 S L644 AND AD<20020131
L666	0 S L644 AND PY<2002
L667	0 S L645 AND AD<20020131
L668	1 S L645 AND PY<2002
L669	1 S L646 AND AD<20020131

(FILE 'HCAPLUS' ENTERED AT 21:51:13 ON 24 APR 2006)
L670 0 S L646 AND PY<2002
L671 0 S L646 AND PY<2002

FILE 'REGISTRY' ENTERED AT 22:08:19 ON 24 APR 2006
L672 1 S L625 AND (359680-46-9)/RN
L673 1 S L625 AND (372074-09-4)/RN
L674 1 S L625 AND (373639-49-7)/RN
L675 1 S L626 AND (866724-09-6)/RN
L676 1 S L626 AND (364319-10-8)/RN
L677 1 S L626 AND (264872-90-4)/RN
L678 1 S L627 AND (162715-54-0)/RN
L679 1 S L628 AND (436104-26-6)/RN

L3
L4
L5
L6

s 1625 and (359680-46-9)/rn
1 (359680-46-9)/RN
L672 1 L625 AND (359680-46-9)/RN

=> d sqide

L672 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 359680-46-9 REGISTRY
CN L-Arginine, L-valyl-L- α -aspartyl-L- α -aspartyl-L-alanyl-L-seryl-
L-lysyl-L-histidyl-L-threonylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4253: PN: WO0131019 PAGE: 810 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001031019
	claimed PAGE
	810

SEQ 1 VDDASKHTGR
=====

HITS AT: 1-8

MF C43 H72 N16 O17


SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
(Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 1625 and (372074-09-4)/rn
1 (372074-09-4)/RN
L673 1 L625 AND (372074-09-4)/RN

=> d sqide

L673 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 372074-09-4 REGISTRY
CN Glycine, L-valyl-L- α -glutamyl-L-glutaminyl-O-phosphono-L-threonyl-L-prolyl-L-lysyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 75: PN: WO0183518 SEQID: 64 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 9
NTE modified (modifications unspecified)

type	location	description
modification	Thr-4	phosphono<PO2>


PATENT ANNOTATIONS (PNTE):
Sequence |Patent
Source |Reference
=====+=====+=====
Not Given|WO2001083518
|claimed
|SEQID 64

SEQ 1 VEQTPKKPG
=====

HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C43 H75 N12 O17 P
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Cplus document type: Patent
RL.P Roles from patents: BIOL (Biological study)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 1625 and (373639-49-7)/rn
1 (373639-49-7)/RN
L674 1 L625 AND (373639-49-7)/RN

=> d sqide

L674 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN **373639-49-7** REGISTRY
CN Glycine, L-valyl-L- α -glutamyl-L-glutaminyl-L-threonyl-L-prolyl-L-lysyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 44: PN: WO0183518 SEQID: 31 unclaimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 9

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001083518
	unclaimed
	SEQID 31


SEQ 1 VEQTPKKPG
=====

HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C43 H74 N12 O14
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PRP (Properties)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPUS (1907 TO DATE)

=> s 1626 and (866724-09-6)/rn
1 (866724-09-6)/RN
L675 1 L626 AND (866724-09-6)/RN

=> d sqide

L675 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN **866724-09-6** REGISTRY

CN Cyclo(L-asparaginyl-L-α-glutamyl-L-asparaginyl-L-threonylglycyl-L-isoleucyl) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 117: PN: US20050203025 SEQID: 1027 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 6

NTE cyclic

PATENT ANNOTATIONS (PNTE):

Sequence |Patent

Source |Reference

=====+=====

Not Given|US2005203025

|claimed

|SEQID 1027

SEQ 1 NENTGI


=====

HITS AT: 1-3, 2-6

MF C25 H40 N8 O11

SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA CAplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 1626 and (364319-10-8)/rn
 1 (364319-10-8)/RN
 L676 1 L626 AND (364319-10-8)/RN

=> d sqide

L676 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
 RN **364319-10-8** REGISTRY
 CN L-Glutamic acid, L- α -glutamyl-L-asparaginyl-L-seryl-L-alanyl-L-valyl-L- α -aspartyl-L- α -glutamyl- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 55: PN: WO0147944 SEQID: 7922 claimed sequence
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 8

PATENT ANNOTATIONS (PNTE):

Sequence |Patent

Source |Reference

=====+=====

Not Given|WO2001047944
 |claimed
 |SEQID 7922

SEQ 1 ENSAVDEE

=====

HITS AT: 1-8


MF C34 H53 N9 O19

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER
 DT.CA CAPLUS document type: Patent
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 OCCU (Occurrence); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 1626 and (264872-90-4)/rn
 1 (264872-90-4)/RN
 L677 1 L626 AND (264872-90-4)/RN

=> s 1627 and (162715-54-0)/rn
 1 (162715-54-0)/RN
 L678 1 L627 AND (162715-54-0)/RN

=> d sqide

L678 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN **162715-54-0** REGISTRY

CN L-Methionine, N-[N2-[N-[1-[N2-[N-[N-[N2-[N-[N-(N-L-tyrosyl-L-tyrosyl)glycyl]-L-alanyl]-L-lysyl]-L-alanyl]-L-tyrosyl]-L-arginyl]-L-prolyl]-L-α-aspartyl]-L-lysyl]- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 12

SEQ 1 YYGAKAYRPD KM

===== ==

HITS AT: 5-12

MF C67 H99 N17 O18 S

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)


Absolute stereochemistry.

PAGE 1-A



HO—

PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 1628 and (436104-26-6)/rn

L679

=> d sqide

L679 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

SEQ 1 DFOSGOHVIV R

HITS AT: 3-10

MF C56 H88 N18 O17


SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 1638 and py<2002
21808456 PY<2002
L652 3 L638 AND PY<2002

=> s 1651 or 1652
L653 3 L651 OR L652

=> d ibib tot

L653 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:126741 HCAPLUS
DOCUMENT NUMBER: 136:166060
TITLE: Antigenic peptides from Neisseria meningitidis and
Neisseria gonorrhoeae
INVENTOR(S): Galeotti, Cesira; Grandi, Guido; Massignani, Vega;
Mora, Mariarosa; Pizza, Mariagrazia; Rappuoli, Rino;
Ratti, Giulio; Scarlato, Vincenzo; Scarselli, Maria
PATENT ASSIGNEE(S): Chiron S.p.A., Italy
SOURCE: PCT Int. Appl., 974 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001031019 A2		20010503	WO 2000-IB1661	20001030
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1999-PV162616	19991029

L653 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:816698 HCAPLUS
DOCUMENT NUMBER: 135:366771
TITLE: Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same
INVENTOR(S): Nash, Piers; Pawson, Tony; Tang, Xiaojing; Tyers, Mike
PATENT ASSIGNEE(S): Mount Sinai Hospital, Can.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083518	A2	20011108	WO 2001-CA632	20010504 <--
WO 2001083518	A3	20020718		
WO 2001083518	C2	20021205		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2407945 AA 20011108 CA 2001-2407945 20010504 <--
AU 2001058093 A5 20011112 AU 2001-58093 20010504 <--
EP 1283879 A2 20030219 EP 2001-931258 20010504 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004072319 A1 20040415 US 2003-275427 20031110
PRIORITY APPLN. INFO.: US 2000-202166P P 20000504
US 2001-263774P P 20010124
WO 2001-CA632 W 20010504

OTHER SOURCE(S): MARPAT 135:366771

L653 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:400021 HCAPLUS

DOCUMENT NUMBER: 135:240910

TITLE: Antigenic peptides from Neisseria meningitidis and
Neisseria gonorrhoeae

INVENTOR(S): Galeotti, Cesira; Grandi, Guido; Massignani, Vega;
Mora, Mariarosa; Pizza, Mariagrazia; Rappuoli, Rino;
Ratti, Giulio; Scarlato, Vincenzo; Scarselli, Maria

PATENT ASSIGNEE(S): Chiron Spa, Italy

SOURCE: PCT Int. Appl., 947 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001031019 A2		20010503	WO 2000-IB1661	20001030
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1999-PV162616	19991029

=> d hitrn 1-3

L653 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

IT 359680-46-9

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(amino acid sequence; Neisseria meningitidis and N. gonorrhoeae
antigens and the genes encoding them for use as vaccine and diagnostic
comps.)

L653 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

IT 372074-09-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)

(Cdc4 protein binding by; mols. that modulate ubiquitin-dependent
proteolysis and methods for identifying same comprising or interacting
with CPD motif (Cdc4 Phospho-Degron motif) in relation to SCF complex
or Cdc4 protein)

IT 373639-49-7

RL: PRP (Properties)

(unclaimed sequence; mols. that modulate ubiquitin-dependent proteolysis and methods for identifying same)

L653 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

IT **359680-46-9**

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antigenic peptides from *Neisseria meningitidis* and *Neisseria gonorrhoeae*)

ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1089072 HCAPLUS
 DOCUMENT NUMBER: 143:379863
 TITLE: Cell adhesion recognition peptide sequences for
 modulating nonclassical cadherin-mediated functions
 INVENTOR(S): Blaschuk, Orest W.; Gour, Barbara J.; Symonds, James
 Matthew; Byers, Stephen
 PATENT ASSIGNEE(S): Adherex Technologies, Inc., Can.
 SOURCE: U.S. Pat. Appl. Publ., 121 pp., Cont.-in-part of U.S.
 Ser. No. 759,507.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 12
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005203025	A1	20050915	US 2004-4107	20041203
US 6472367	B1	20021029	US 1998-73040	19980505 <--
US 6358920	B1	20020319	US 1998-187859	19981106 <--
US 2002123044	A1	20020905	US 1999-234395	19990120 <--
US 6680175	B2	20040120		
US 2002169106	A1	20021114	US 1999-264516	19990308 <--
US 6593297	B2	20030715		
US 6433149	B1	20020813	US 1999-305927	19990505 <--
US 2002146687	A1	20021010	US 1999-305928	19990505 <--
US 6682901	B2	20040127		
US 6638911	B1	20031028	US 2000-535852	20000327 <--
US 6569996	B1	20030527	US 2001-839542	20010420 <--
US 2003082166	A1	20030501	US 2001-6869	20011203 <--
US 6962969	B2	20051108		
AU 2002029228	A5	20020516	AU 2002-29228	20020328
AU 778119	B2	20041118		
US 2003096746	A1	20030522	US 2002-141357	20020507
US 2003229199	A1	20031211	US 2003-395032	20030321
US 2004229811	A1	20041118	US 2003-654578	20030903
US 2004248219	A1	20041209	US 2004-759379	20040116
US 2004248220	A1	20041209	US 2004-759507	20040116
PRIORITY APPLN. INFO.:			US 1998-73040	A2 19980505
			US 1998-187859	A2 19981106
			US 1999-234395	A2 19990120
			US 1999-264516	A2 19990308
			US 1999-305927	A1 19990505
			US 1999-305928	A1 19990505
			US 2000-535852	A1 20000327
			US 2001-839542	A1 20010420
			US 2001-6869	A2 20011203
			US 2002-141357	B2 20020507
			US 2003-395032	A2 20030321
			US 2003-654578	A2 20030903
			US 2004-759379	A2 20040116
			US 2004-759507	A2 20040116
			AU 1999-35906	A3 19990505

OTHER SOURCE(S): MARPAT 143:379863
 IT 866724-09-6
 RL: BSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cadherin-6 derived peptide; cell adhesion recognition peptide
 sequences for modulating nonclassical cadherin-mediated functions)

L656 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:624615 HCAPLUS

DOCUMENT NUMBER: 135:328135
TITLE: Nucleic acids containing single nucleotide
polymorphisms in the human genome
INVENTOR(S): Shimkets, Richard A.; Leach, Martin
PATENT ASSIGNEE(S): Curagen Corp., USA
SOURCE: PCT Int. Appl., 4144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047944	A2	20010705	WO 2000-US35498	20001228 <--
WO 2001047944	A3	20030220		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2395926	AA	20010705	CA 2000-2395926	20001228 <--
AU 2001029145	A5	20010709	AU 2001-29145	20001228 <--
EP 1244688	A1	20021002	EP 2000-993615	20001228 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: US 1999-173419P P 19991228
WO 2000-US35498 W 20001228

IT 364319-10-8

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(polymorphic site sequence; nucleic acids containing single nucleotide polymorphisms in the human genome)

L656 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:260339 HCAPLUS
DOCUMENT NUMBER: 132:307253
TITLE: Treatment of inflammatory disease
INVENTOR(S): Panayi, Gabriel Stavros; Corrigall, Valerie Mary; Bodman-Smith, Mark Duncan; Fife, Mark Stewart; Lanchbury, Jeremy Shaun
PATENT ASSIGNEE(S): King's College London, UK
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021995	A1	20000420	WO 1999-GB3316	19991008 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2344590 AA 20000420 CA 1999-2344590 19991008 <--
 AU 9962154 A1 20000501 AU 1999-62154 19991008 <--
 AU 754888 B2 20021128
 EP 1117685 A1 20010725 EP 1999-949169 19991008 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2003523167 T2 20030805 JP 2000-575897 19991008 <--
 US 6995240 B1 20060207 US 2001-806955 20010711 <--
 PRIORITY APPLN. INFO.: GB 1998-22115 A 19981009
 WO 1999-GB3316 W 19991008

IT 264872-90-4

RL: PRP (Properties)

(unclaimed sequence; treatment of inflammatory disease)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:471011 HCAPLUS

DOCUMENT NUMBER: 122:259576

TITLE: Kinetic characterization of a peptide inhibitor of
trypsin isolated from a synthetic peptide
combinatorial library

AUTHOR(S): Coombs, Gary S.; Hazzard, James; Corey, David R.

CORPORATE SOURCE: Howard Hughes Med. Inst., Univ. Texas Southwestern
Med. Cent., Dallas, TX, 75235, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1995
, 5(6), 611-14

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 162715-54-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); BIOL (Biological study)
(structure-activity relations of trypsin synthetic peptide inhibitors)

ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:450006 HCAPLUS
 DOCUMENT NUMBER: 137:30235
 TITLE: Nucleic acid and polypeptides and their peptides as markers detectable by two-dimensional electrophoresis of brain tissue and their uses for diagnosis and treatment of Alzheimer's disease
 INVENTOR(S): Herath, Herath Mudiyanselage Athula Chandrasiri; Parekh, Rajesh Bhikhu; Rohlff, Christian
 PATENT ASSIGNEE(S): Oxford Glycosciences (UK) Ltd., UK
 SOURCE: PCT Int. Appl., 427 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046767	A2	20020613	WO 2001-GB5289	20011129 <--
WO 2002046767	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002022108	A5	20020618	AU 2002-22108	20011129 <--
EP 1379879	A2	20040114	EP 2001-999816	20011129 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003064411	A1	20030403	US 2001-14340	20011210 <--
US 2003092614	A1	20030515	US 2001-14338	20011210 <--
PRIORITY APPLN. INFO.:			US 2000-254431P	P 20001208
			WO 2001-GB5289	W 20011129

IT **436104-26-6**

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (amino acid sequence; nucleic acid and polypeptides and their peptides as markers detectable by two-dimensional electrophoresis of brain tissue and their uses for diagnosis and treatment of Alzheimer's disease)

NSWER 67 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1997:525868 HCAPLUS
 DOCUMENT NUMBER: 127:204002
 TITLE: Genes for proteins that interact with presenilins and
 their role in familial Alzheimer's disease and
 therapeutic use
 INVENTOR(S): St. George-Hyslop Peter H.; Fraser, Paul E.; Rommens,
 Johanna M.
 PATENT ASSIGNEE(S): HSC Research and Development Ltd. Partnership, Can.;
 Governing Council of the University of Toronto;
 Fraser, Paul E.; Rommens, Johanna M.
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727296	A1	19970731	WO 1997-CA51	19970127 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5986054	A	19991116	US 1996-592541	19960126 <--
CA 2244412	AA	19970731	CA 1997-2244412	19970127 <--
AU 9712992	A1	19970820	AU 1997-12992	19970127 <--
AU 732508	B2	20010426		
EP 876483	A1	19981111	EP 1997-900531	19970127 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
JP 2000506375	T2	20000530	JP 1997-526378	19970127 <--
CA 2259618	AA	19980115	CA 1997-2259618	19970704 <--
WO 9801549	A2	19980115	WO 1997-CA475	19970704 <--
WO 9801549	A3	19980409		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9732519	A1	19980202	AU 1997-32519	19970704 <--
EP 914428	A2	19990512	EP 1997-928092	19970704 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
JP 2000516087	T2	20001205	JP 1998-504606	19970704 <--
PRIORITY APPLN. INFO.: US 1996-592541 P 19960126 US 1996-21673P P 19960705 US 1996-21700P P 19960712 US 1996-29895P P 19961108 US 1997-34590P P 19970102 US 1995-431048 A2 19950428 US 1995-496841 A2 19950628 US 1995-509359 A2 19950731 WO 1997-CA51 W 19970127 WO 1997-CA475 W 19970704				
AB Several human genes for proteins that interact with the presenilins, the proteins involved in the etiol. of familial Alzheimer's disease are cloned				

and characterized. Mutations in the presenilin-interacting protein genes, even in the absence of defects in the presenilins, may be causative of Alzheimer's Disease. The genes and proteins or their derivs. are useful in screening and diagnosing Alzheimer's disease, in identifying and developing therapeutics for treatment of Alzheimer's disease, and in producing cell lines and transgenic animals useful as models of Alzheimer's disease. The proteins identified the S5a subunit of the 26S proteasome, armadillo repeat proteins GT24 and p0071, G protein Rab11, retinoid X receptor β , a cytoplasmic chaperonin and a set of 3 novel proteins. These proteins were identified as ligands for the loop generated by transmembrane domains 6 and 7 of presenilin 1 using a yeast two-assay.

ANSWER 65 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:29110 HCAPLUS

DOCUMENT NUMBER: 128:176678

TITLE: Characterization and chromosomal localization of PTPRO, a novel receptor protein tyrosine phosphatase, expressed in hematopoietic stem cells

AUTHOR(S): Avraham, Shalom; London, Roanna; Tulloch, Graham A.; Ellis, Martin; Fu, Yigong; Jiang, Shuxian; White, Robert A.; Painter, Christopher; Steinberger, A. A.; Avraham, Hava

CORPORATE SOURCE: Divisions Experimental Medicine Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Institutes Medicine, Boston, MA, 02115, USA

SOURCE: Gene (1997), 204(1/2), 5-16

CODEN: GENED6; ISSN: 0378-1119

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Hematopoietic stem cells (HSCs) support blood cells throughout life by utilizing their self-renewing and multilineage differentiating capabilities. Hematopoietic growth factors mediate their effects on stem cells by the tyrosine phosphorylation of proteins. Regulation of tyrosine phosphorylation is partially mediated by protein tyrosine phosphatases (PTPases). A possible mechanism by which hematopoietic stem cells maintain their self-renewing capacity and undifferentiated state is by controlling the balanced and opposing actions of protein tyrosine kinases (PTKs), receptors for growth factors, and PTPases. We have characterized the expression of PTPases in 5-fluorouracil (5-FU)-treated murine bone marrow cells, which represent a very primitive population of progenitors enriched for reconstituting stem cells, by using a consensus polymerase chain reaction (PCR) method. Several PTPases were expressed abundantly in the 5-FU-treated bone marrow stem cells. A novel PTP, termed protein tyrosine phosphatase receptor omicron (PTPRO), which is related to the homotypically adhering κ , μ and PCP-2 receptor-type tyrosine phosphatases, was identified and characterized. We have cloned the murine and full-length human PTPRO cDNAs which share 89% homol., indicating that PTPRO is highly conserved between these species. The human PTPRO cDNA clone encodes a polypeptide of 1439 amino acids (aa) and has a calculated mol. mass of .apprx. 162 kDa. PTPRO consists of an extracellular segment containing a MAM domain, an Ig (Ig) domain, four fibronectin-type III (FN-III) repeats, a transmembrane segment, and two tandem intracellular PTP domains. The human PTPRO gene was assigned to human chromosome 1p35-pter using Southern blot analyses of genomic DNAs from rodent/human somatic hybrid cell lines containing human chromosome 1 or the p35-pter region of the chromosome. The mouse Ptpro gene was mapped to chromosome 4, closely linked to D4Mit16 and Elpl (elliptocytosis-1), by using genomic DNAs from a (C57BL/6J + Mus spretus)F1 + Mus spretus backcross. In fetal tissues, PTPRO expression was observed in brain and lung, whereas lower levels were observed in the kidney. In adult tissues PTPRO was less restricted and was observed in the lung, heart, skeletal muscle, prostate, testis, and in various areas of the brain, indicating that PTPRO expression is developmentally regulated. Expression of PTPRO was also observed in human CD34+ bone marrow cells and 5-FU-treated murine primitive stem cells. These results suggest a potential role for PTPRO in stem cell adhesion and in mediating homophilic cell-cell interactions in other cell types.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 63 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:352937 HCAPLUS

DOCUMENT NUMBER: 129:50518

TITLE: isolation, sequence, diagnostic and therapeutic use of human polyhomeotic 2 (hph2) and protein

INVENTOR(S): Randazzo, Filippo

PATENT ASSIGNEE(S): Chiron Corp., USA

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9822585	A1	19980528	WO 1997-US21220	19971119 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9854490	A1	19980610	AU 1998-54490	19971119 <--
EP 948618	A1	19991013	EP 1997-948414	19971119 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6140483	A	20001031	US 1997-974380	19971119 <--
US 6673911	B1	20040106	US 2000-546977	20000411 <--
US 6677117	B1	20040113	US 2000-654466	20000901 <--
US 2004006210	A1	20040108	US 2003-435512	20030509
PRIORITY APPLN. INFO.:			US 1996-31396P	P 19961119
			US 1997-974380	A3 19971119
			US 1997-974600	B1 19971119
			WO 1997-US21220	W 19971119
			US 2000-546977	A1 20000411

AB A human oncogene and its expression products can be used as diagnostic, prognostic, and therapeutic tools for neoplastic disorders. Nucleotide sequences of the gene can also be used to identify a p34.3 region of a human chromosome 1. Cloning and sequencing of the hph2 gene was performed. Thus, expression vectors containing the hph2 coding sequence and a gene promoter element were constructed. The hph2 protein, hph2 fusion proteins (containing ≥ 14 contiguous amino acids from hph2), and hph2-binding proteins are also claimed. The hph2 protein and gene can be used to either detect human chromosome 1 (specifically the p34.3 region), or a genetic predisposition to human neoplasia, or in a therapeutic composition for treating neoplasia. The therapeutic composition uses antisense hph2 polynucleotides and a pharmaceutically acceptable carrier. The hph2 gene or protein can be used to induce a cell to change its pattern of differentiation. Such cells include adult spleen, prostate, thymus, testis, ovary, small intestine, mucosal lining of the colon, and peripheral blood leukocytes. Other cells include heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, bone marrow, and appendix.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 60 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:621307 HCAPLUS
 DOCUMENT NUMBER: 129:226647
 TITLE: Cloning and cDNA and deduced amino acid sequences of
 28 human secreted proteins
 INVENTOR(S): Ruben, Steven M.; Rosen, Craig A.; Li, Yi; Zeng,
 Zhizhen; et al.
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: PCT Int. Appl., 202 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 57
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840483	A2	19980917	WO 1998-US4858	19980312 <--
WO 9840483	A3	19981119		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,				
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				
UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,				
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,				
GA, GN, ML, MR, NE, SN, TD, TG				
CA 2283678	AA	19980917	CA 1998-2283678	19980312 <--
AU 9865521	A1	19980929	AU 1998-65521	19980312 <--
EP 973892	A2	20000126	EP 1998-911597	19980312 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI				
JP 2001524814	T2	20011204	JP 1998-539800	19980312 <--
EP 1333092	A2	20030806	EP 2003-6709	19980312 <--
EP 1333092	A3	20031210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI				
CA 2291260	AA	19981210	CA 1998-2291260	19980604 <--
EP 1428833	A2	20040616	EP 2004-1119	19980604 <--
EP 1428833	A3	20040707		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI, CY				
US 6448230	B1	20020910	US 1998-152060	19980911 <--
US 2002076756	A1	20020620	US 2001-853161	20010511 <--
US 6919433	B2	20050719		
US 2002172994	A1	20021121	US 2001-852797	20010511 <--
US 6878806	B2	20050412		
US 2003225009	A1	20031204	US 2002-58993	20020130 <--
US 6951924	B2	20051004		
US 2005208621	A1	20050922	US 2004-951993	20040929
PRIORITY APPLN. INFO.:			US 1997-40710P	P 19970314
			US 1997-40762P	P 19970314

ANSWER 55 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:512307 HCAPLUS

DOCUMENT NUMBER: 131:270903

TITLE: APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif

AUTHOR(S): Bates, Elizabeth E. M.; Fournier, Nathalie; Garcia, Eric; Valladeau, Jenny; Durand, Isabelle; Pin, Jean-Jacques; Zurawski, Sandra M.; Patel, Sejal; Abrams, John S.; Lebecque, Serge; Garrone, Pierre; Saeland, Sem

CORPORATE SOURCE: Laboratory for Immunological Research, Dardilly, 69571, Fr.

SOURCE: Journal of Immunology (1999), 163(4), 1973-1983

CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors have identified a novel member of the calcium-dependent (C-type) lectin family. This mol., designated DCIR (for dendritic cell (DC) immunoreceptor), is a type II membrane glycoprotein of 237 aa with a single carbohydrate recognition domain (CRD), closest in homol. to those of the macrophage lectin and hepatic asialoglycoprotein receptors. The intracellular domain of DCIR contains a consensus immunoreceptor tyrosine-based inhibitory motif. A mouse cDNA, encoding a homologous protein has been identified. Northern blot anal. showed DCIR mRNA to be predominantly transcribed in hematopoietic tissues. The gene encoding human DCIR was localized to chromosome 12p13, in a region close to the NK gene complex. Unlike members of this complex, DCIR displays a typical lectin CRD rather than an NK cell type extracellular domain, and was expressed on DC, monocytes, macrophages, B lymphocytes, and granulocytes, but not detected on NK and T cells. DCIR was strongly expressed by DC derived from blood monocytes cultured with GM-CSF and IL-4. DCIR was mostly expressed by monocyte-related rather than Langerhans cell related DC obtained from CD34+ progenitor cells. Finally, DCIR expression was down-regulated by signals inducing DC maturation such as CD40 ligand, LPS, or TNF- α . Thus, DCIR is differentially expressed on DC depending on their origin and stage of maturation/activation. DCIR represents a novel surface mol. expressed by Ag presenting cells, and of potential importance in regulation of DC function.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 51 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:185732 HCAPLUS

DOCUMENT NUMBER: 133:38955

TITLE: Identification of an interleukin-3-regulated aldoketo reductase gene in **myeloid** cells which may function in autocrine regulation of myelopoiesis

AUTHOR(S): Du, Yang; Tsai, Schickwann; Keller, Jonathan R.; Williams, Simon C.

CORPORATE SOURCE: Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX, 79430, USA

SOURCE: Journal of Biological Chemistry (2000), 275(10), 6724-6732

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The EML hematopoietic progenitor cell line is a model system for studying mol. events regulating **myeloid** commitment and terminal differentiation. We used representational difference anal. to identify genes that are expressed differentially during **myeloid** differentiation of EML cells. One gene (named mAKRa) encoded a novel member of the aldoketo reductase (AKR) superfamily of cytosolic NAD(P)(H)-dependent oxidoreductases. MAKRa mRNA was detected in murine hematopoietic tissues including bone **marrow**, spleen, and thymus. In **myeloid** cell lines, mAKRa was expressed at highest levels in cells representative of promyelocytes. MAKRa mRNA levels increased rapidly in response to interleukin-3 over the first 24 h of EML cell differentiation when the cells undergo lineage commitment and extensive proliferation. MAKRa mRNA levels decreased later in the differentiation process particularly when the EML cells were cultured with granulocyte/macrophage colony-stimulating factor and retinoic acid to induce terminal granulocytic maturation. MAKRa mRNA levels decreased during retinoic acid-induced terminal granulocytic differentiation of the MPRO promyelocyte cell line. AKRs act as mol. switches by catalyzing the interconversion or inactivation of bioactive mols. including steroids and prostaglandins. We propose that mAKRa may catalyze the production or catabolism of autocrine factors that promote the proliferation and/or lineage commitment of early **myeloid** progenitors.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 43 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:802702 HCAPLUS

DOCUMENT NUMBER: 134:84910

TITLE: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

AUTHOR(S): Parrish-Novak, Julia; Dillon, Stacey R.; Nelson, Andrew; Hammond, Angle; Sprecher, Cindy; Gross, Jane A.; Johnston, Janet; Madden, Karen; Xu, Wenfeng; West, Jim; Schrader, Sara; Burkhead, Steve; Heipel, Mark; Brandt, Cameron; Kuijper, Joseph L.; Kramer, Janet; Conklin, Darrell; Presnell, Scott R.; Berry, Jon; Shiota, Faith; Bort, Susan; Hambly, Kevin; Mudri, Sherri; Clegg, Chris; Moore, Margaret; Grant, Francis J.; Lofton-Day, Catherine; Gilbert, Teresa; Raymond, Fenella; Ching, Andrew; Yao, Lena; Smith, Deb; Webster, Philippa; Whitmore, Theodore; Maurer, Mark; Kaushansky, Kenneth; Holly, Rick D.; Foster, Don

CORPORATE SOURCE: Departments of Functional Cloning, Immunology, Protein Biochemistry, Biomol. Informatics, and Genetics, ZymoGenetics, Inc., Seattle, WA, 98102, USA

SOURCE: Nature (London) (2000), 408(6808), 57-63

CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cytokines are important in the regulation of hematopoiesis and immune responses, and can influence lymphocyte development. Here the authors have identified a class I cytokine receptor that is selectively expressed in lymphoid tissues and is capable of signal transduction. The full-length receptor was expressed in BaF3 cells, which created a functional assay for ligand detection and cloning. Conditioned media from activated human CD3+ T cells supported proliferation of the assay cell line. The authors constructed a complementary DNA expression library from activated human CD3+ T cells, and identified a cytokine with a four-helix-bundle structure using functional cloning. This cytokine is most closely related to IL2 and IL15, and has been designated IL21 with the receptor designated IL21 R. In vitro assays suggest that IL21 has a role in the proliferation and maturation of natural killer (NK) cell populations from bone marrow, in the proliferation of mature B-cell populations co-stimulated with anti-CD40, and in the proliferation of T cells co-stimulated with anti-CD3.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 42 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:861791 HCAPLUS
 DOCUMENT NUMBER: 134:25786
 TITLE: Cloning of cDNA for novel cytokine C121 from mice and human
 INVENTOR(S): Tulin, Edgardo E.; Onoda, Nobuhisa
 PATENT ASSIGNEE(S): Chugai Research Institute for Molecular Medicine, Inc., Japan
 SOURCE: PCT Int. Appl., 128 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2000073442	A1	20001207	WO 2000-JP3505	20000531 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 1999-154365 A 19990601

AB The cDNA encoding a novel cytokine C121 is successfully isolated from the cDNA library prepared from ST2 cells, a mutant derived from mouse **myeloid** stroma-origin cell line Ba/F3, by using a retrovirus-derived vector. Cytokine C121 is a complete protein comprising a partial amino acid sequence of mouse ISF (immune suppressor factor) protein. It occurs as a soluble protein and a cell membrane-attached protein and both of these types show an activity of supporting the proliferation of S21 cells. Also, a human cDNA corresponding to mouse ISF gene is successfully isolated from a human kidney-origin cDNA library. Methods of recombinant preparation of cytokine C121, antibodies to cytokine C121, and use of cell FERM BP-6708 for screening agonists or antagonists of cytokine C121 are also claimed.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 39 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:113539 HCAPLUS
DOCUMENT NUMBER: 135:222126
TITLE: Cloning and characterization of a novel ITIM
containing lectin-like immunoreceptor LLIR and its two
transmembrane region deletion variants
AUTHOR(S): Huang, Xin; Yuan, Zhenglong; Chen, Guoyou; Zhang,
Minghui; Zhang, Weiping; Yu, Yizhi; Cao, Xuetao
CORPORATE SOURCE: Department of Immunology, Second Military Medical
University, Shanghai, 200433, Peop. Rep. China
SOURCE: Biochemical and Biophysical Research Communications (
2001), 281(1), 131-140
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A novel full-length cDNA was cloned from human dendritic cells (DC) by
subtractive cloning and RACE. The deduced protein is a type II
lectin-like membrane protein that contains an ITIM proximal to N terminal
and is designated as lectin-like immunoreceptor (LLIR). The gene of LLIR
is located in a region of chromosomal 12p13 and shows highest homologous
with ASGPR. Two alternatively spliced transmembraneless variants of LLIR
were identified by RT-PCR and named as LLIRv1 and LLIRv2. RT-PCR and
immunoblotting anal. revealed that LLIR was expressed with much higher
level in immature DC than in mature DC. The ITIM in LLIR was demonstrated
to bind SHP-1 in HL-60 cell after the tyrosine had been phosphorylated.
In addition, the mRNA expression level of LLIRv2 was raised when leukemia
cells were induced to differentiate by PMA. (c) 2001 Academic Press.
REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:360044 HCAPLUS
DOCUMENT NUMBER: 134:365716
TITLE: A surface protein of hematopoietic stem cells of the lymphoid line and of NK cells, a cDNA encoding it and its uses
INVENTOR(S): Kirszenbaum, Marek; Le Discorde, Magali; Prost, Stephane
PATENT ASSIGNEE(S): Commissariat a l'Energie Atomique, Fr.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2001034653	A2	20010517	WO 2000-FR3137	20001110 <--
WO 2001034653	A3	20020207		
W: CA, IL, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
FR 2801056	A1	20010518	FR 1999-14241	19991112 <--
FR 2801056	B1	20030328		
CA 2389204	AA	20010517	CA 2000-2389204	20001110 <--
EP 1228212	A2	20020807	EP 2000-981414	20001110 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2003516130	T2	20030513	JP 2001-537364	20001110 <--
PRIORITY APPLN. INFO.:			FR 1999-14241	A 19991112
			WO 2000-FR3137	W 20001110

AB The invention concerns a protein present at the surface of hematopoietic stem cells of the lymphoid line and mature NK cells, the corresponding isolated cDNA sequence and their uses as marker of said cells and for preparing antibodies directed against said protein. The invention also concerns the uses of said antibodies for selecting cells expressing at their surface said protein. The protein, the KLIP-1 antigen, has an N-terminal signal peptide followed by an extracellular domain, five transmembrane domains, and a C-terminal cytoplasmic domain and an apparent mol. weight of 36 to 38 kDa. The gene was identified as a natural killer cell-specific marker by representational difference anal.

ANSWER 36 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:482503 HCAPLUS

DOCUMENT NUMBER: 135:209001

TITLE: PRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and promyelocytic leukemia (PML)-RA receptor α in acute promyelocytic leukemia cells

AUTHOR(S): Moog-Lutz, Christel; Peterson, Erik J.; Lutz, Pierre G.; Eliason, Steve; Cave-Riant, Florence; Singer, Andrew; Di Gioia, Yolande; Dmowski, Sally; Kamens, Joanne; Cayre, Yvon E.; Koretzky, Gary

CORPORATE SOURCE: Unite INSERM 417, Hopital Saint-Antoine, Paris, 75012, Fr.

SOURCE: Journal of Biological Chemistry (2001), 276(25), 22375-22381

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The t(15;17) translocation, found in 95% of acute promyelocytic leukemia, encodes a promyelocytic leukemia (PML)-retinoic acid receptor α (RAR α) fusion protein. Complete remission of acute promyelocytic leukemia can be obtained by treating patients with all-trans retinoic acid, and PML-RAR α plays a major role in mediating retinoic acid effects in leukemia cells. A main model proposed for acute promyelocytic leukemia is that PML-RAR α exerts its oncogenic effects by repressing the expression of retinoic acid-inducible genes critical to **myeloid** differentiation. By applying subtraction cloning to acute promyelocytic leukemia cells, the authors identified a retinoic acid-induced gene, PRAM-1 (PML-RAR α target gene encoding an Adaptor Mol.-1), which encodes a novel adaptor protein sharing structural homologies with the SLAP-130/fyb adaptor. PRAM-1 is expressed and regulated during normal human myelopoiesis. In U937 **myeloid** precursor cells, PRAM-1 expression is inhibited by expression of PML-RAR α in the absence of ligand and de novo superinduced by retinoic acid. PRAM-1 assoc. with other adaptors, SLP-76 and SKAP-55HOM, in **myeloid** cell lines and with protein tyrosine kinase lyn. By providing the first evidence that PML-RAR α dysregulates expression of an adaptor protein, the authors' data open new insights into signaling events that are disrupted during transformation by PML-RAR α and induced by retinoic acid during de novo differentiation of acute promyelocytic leukemia cells.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:676947 HCAPLUS
 DOCUMENT NUMBER: 135:237112
 TITLE: Human FCTR proteins related to growth factors and cDNAs encoding them and their use in drug screening and therapy
 INVENTOR(S): Vernet, Corine A. M.; Fernandes, Elma; Shimkets, Richard A.; Herrmann, John L.; Majumder, Kumud; MacDougall, John; Mishra, Vishnu; Mezes, Peter S.; Rastelli, Luca
 PATENT ASSIGNEE(S): Curagen Corporation, USA
 SOURCE: PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 165
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066747	A2	20010913	WO 2001-US7160	20010305 <--
WO 2001066747	A3	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2401552	AA	20010915	CA 2001-2401552	20010305 <--
EP 1261712	A2	20021204	EP 2001-920218	20010305 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003087816	A1	20030508	US 2001-800198	20010305 <--
JP 2003525634	T2	20030902	JP 2001-565901	20010305 <--
US 2002155115	A1	20021024	US 2001-808602	20010314 <--
AU 2005200106	A1	20050210	AU 2005-200106	20050112
PRIORITY APPLN. INFO.:				
			US 2000-186592P	P 20000303
			US 2000-186718P	P 20000303
			US 2000-187718P	P 20000303
			US 2000-187293P	P 20000306
			US 2000-187294P	P 20000306
			US 2000-190400P	P 20000317
			US 2000-196018P	P 20000407
			US 2001-259548P	P 20010103
			AU 2000-37360	A3 20000309
			WO 2001-US7160	W 20010305

AB Disclosed herein are novel human nucleic acid sequences which encode polypeptides. The proteins are FCTR proteins related to bone morphogenetic protein-1 (BMF1), to vascular endothelial growth factor E (VEGF-E), and to platelet-derived growth factor (PDGF). Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins. The cDNAs for splice variants of these FCTRs were also cloned and sequenced. The gene for human FCTR1, also called platelet-derived growth factor D, was mapped to chromosome 11. The FCTR1 cDNA was expressed in E. coli and 293 cells. FCTR1 was shown to have growth factor activity.

ANSWER 29 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:818857 HCAPLUS

DOCUMENT NUMBER: 136:15814

TITLE: Complete genome sequence of a multiple drug resistant *Salmonella enterica* serovar typhi CT18

AUTHOR(S): Parkhill, J.; Dougan, G.; James, K. D.; Thomson, N. R.; Pickard, D.; Wain, J.; Churcher, C.; Mungall, K. L.; Bentley, S. D.; Holden, M. T. G.; Sebalhia, M.; Baker, S.; Basham, D.; Brooks, K.; Chillingworth, T.; Connerton, P.; Cronin, A.; Davis, P.; Davies, R. M.; Dowd, L.; White, N.; Farrar, J.; Feltwell, T.; Hamlin, N.; Haque, A.; Hien, T. T.; Holroyd, S.; Jagels, K.; Krogh, A.; Larsen, T. S.; Leather, S.; Moule, S.; O'Gaora, P.; Parry, C.; Quail, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, K.; Whitehead, S.; Barrell, B. G.

CORPORATE SOURCE: The Sanger Centre, Wellcome Trust Genome Campus, Cambridge, CBIO ISA, UK

SOURCE: Nature (London, United Kingdom) (2001), 413(6858), 848-852

CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB *Salmonella enterica* serovar typhi (*S. typhi*) is the etiol. agent of typhoid fever, a serious invasive bacterial disease of humans with an annual global burden of .apprx.16 million cases, leading to 600,000 fatalities. Many *S. enterica* serovars actively invade the mucosal surface of the intestine but are normally contained in healthy individuals by the local immune defense mechanisms. However, *S. typhi* has evolved the ability to spread to the deeper tissues of humans, including liver, spleen, and bone marrow. The 4,809,037-bp genome was sequenced for a *S. typhi* (CT18) that is resistant to multiple drugs, revealing the presence of hundreds of insertions and deletions compared with the *Escherichia coli* genome, ranging in size from single genes to large islands. Notably, the genome sequence identifies >200 pseudogenes, several corresponding to genes that are known to contribute to virulence in *Salmonella typhimurium*. This genetic degradation may contribute to the human-restricted host range for *S. typhi*. CT18 harbors a 218,150-bp multiple-drug-resistance IncH1 plasmid (pHCM1), and a 106,516-bp cryptic plasmid (pHCM2), which shows recent common ancestry with a virulence plasmid of *Yersinia pestis*.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 21 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:172445 HCAPLUS

DOCUMENT NUMBER: 136:227977

TITLE: New members of the four-disulfide-core family of
proteinase inhibitors identified by sequence homology
and cDNAs encoding them and their uses

INVENTOR(S): Holtzman, Douglas A.; Goodearl, Andrew D. j.;
McCarthy, Sean A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 138 pp., Cont.-in-part of U. S.
Ser. No. 65,661, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2002028508	A1	20020307	US 2001-790264	20010221 <--
US 2003104447	A1	20030605	US 2002-269353	20021011
US 2005019810	A1	20050127	US 2004-900926	20040728
PRIORITY APPLN. INFO.:			US 1998-65363	B2 19980423
			US 1998-65661	B2 19980423
			US 1998-102705	B2 19980622
			US 1998-124538	B2 19980729
			US 1999-298531	B2 19990423
			US 1999-337930	B2 19990622
			US 1999-363630	B2 19990729
			US 2001-790264	B1 20010221
			US 2002-269353	A1 20021011

AB New members of the four-disulfide-core family of proteinase inhibitors called TANGO-175 and WDNM-2 are identified in mouse and human and cDNAs encoding them are cloned and characterized. In addition to isolated, full-length TANGO-175 TANGO-110, TANGO-125, TANGO-139 and WDNM-2 proteins, the invention further provides fusion proteins, antigenic peptides and antibodies to the proteins. The invention also provides cDNAs, expression vectors, host cells into which the expression vectors have been introduced and non-human transgenic animals in which one of these genes has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compns. of the invention are also provided. A mouse TANGO-175 cDNA was cloned from stimulated bone marrow cells by sequence of comparison of cDNAs selected subtractive hybridization against RNA from unstimulated cells against known sequences. WDNM-2 was identified by searching EST databases for sequences similar to TANGO-175 and WDNM-1. The TANGO-175 gene was widely expressed and was strongly induced in a mouse septic shock model.

ANSWER 20 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:185276 HCAPLUS
 DOCUMENT NUMBER: 136:242898
 TITLE: Screening of peptide libraries to identify highly specific ligands and cognate receptors for cell or tissue-specific targeting
 INVENTOR(S): Arap, Wadih; Pasqualini, Renata
 PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
 SOURCE: PCT Int. Appl., 298 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020722	A2	20020314	WO 2001-US27702	20010907 <--
WO 2002020722	A3	20030206		
WO 2002020722	C2	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421191	AA	20020314	CA 2001-2421191	20010907 <--
AU 2001090652	A5	20020322	AU 2001-90652	20010907 <--
EP 1315965	A2	20030604	EP 2001-970671	20010907 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004515751	T2	20040527	JP 2002-525729	20010907 <--
CA 2496938	AA	20040311	CA 2002-2496938	20021030
WO 2004020999	A1	20040311	WO 2002-US34987	20021030
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002364501	A1	20040319	AU 2002-364501	20021030
EP 1546714	A1	20050629	EP 2002-799873	20021030
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2004048243	A1	20040311	US 2003-363208	20030902
PRIORITY APPLN. INFO.:				
			US 2000-231266P	P 20000908
			US 2001-765101	A 20010117
			US 2001-97651	A 20010117
			WO 2001-US27702	W 20010907
			WO 2002-US27836	A 20020830
			WO 2002-US34987	W 20021030
AB Methods of identify cell or tissue-specific peptide ligands and their cognate receptors for use in targeted drug delivery or gene therapy. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery				

of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed. Screening of a phage display library by direct incubation with bone **marrow** to identify bone **marrow**-specific ligand peptides is demonstrated. The use of circulating antibodies from prostate cancer patients to identify the antigens. One of the antigens, identified as GRP78, was a strong indicator of survival time and could be used as a prognostic marker. Successful targeting of adeno-associated virus-based vectors to vascular endothelium is demonstrated.

ANSWER 15 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:522023 HCAPLUS
 DOCUMENT NUMBER: 137:90875
 TITLE: Adenovirus type 11 and 4 based-viral vector for gene therapy
 INVENTOR(S): Wadell, Goeran; Mei, Ya-Fang; Segerman, Anna; Skog, Johan; Lindman, Kristina
 PATENT ASSIGNEE(S): Swed.
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002053759	A1	20020711	WO 2002-SE13	20020104 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1348030	A1	20031001	EP 2002-727029	20020104 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004136958	A1	20040715	US 2004-250304	20040123
PRIORITY APPLN. INFO.:			SE 2001-35	A 20010104
			US 2001-260358P	P 20010108
			WO 2002-SE13	W 20020104

AB The present invention concerns the field of gene therapy and in particular the use of specific adenoviral vector systems for gene therapy, said vector systems offering enhanced efficiency and specificity for gene delivery. Adenovirus types 11p and 4p show a higher binding affinity and infectivity than type 5 for endothelial cell and carcinoma cell lines. A high binding affinity of Ad 11p to several hematopoietic cell lines has also been observed. Ad 11p exhibited high binding efficiency to CD1a dendritic cells. Adenovirus type 11p shows a stronger binding to cells for neural origin, such as glioblastoma, neuroblastoma and medulloblastoma. The fact that adenovirus type 11 has a comparatively low prevalence in society, together with its high affinity and infectivity, makes it very suitable for use in gene therapy.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 9 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:261946 HCAPLUS
 DOCUMENT NUMBER: 138:297608
 TITLE: Peptides from various peptide libraries, their dimers and fusion proteins as modulators of insulin and IGF-1 receptors
 INVENTOR(S): Pillutla, Renuka; Dedova, Olga; Blume, Arthur J.; Goldstein, Neil I.; Brissette, Renee; Wang, Pinger; Liu, Hao; Hsiao, Ku-Chuan; Lennick, Michael; Fletcher, Paul
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; DGI Biotechnologies
 SOURCE: PCT Int. Appl., 372 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003027246	A2	20030403	WO 2002-US30412	20020924
WO 2003027246	A3	20030731		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003195147	A1	20031016	US 2001-962756	20010924 <--
US 6875741	B2	20050405		
CA 2459999	AA	20030403	CA 2002-2459999	20020924
EP 1432433	A2	20040630	EP 2002-775987	20020924
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005505579	T2	20050224	JP 2003-530818	20020924
PRIORITY APPLN. INFO.:			US 2001-962756	A2 20010924
			US 1998-146127	B2 19980902
			US 2000-538038	A2 20000329
			WO 2002-US30412	W 20020924

AB Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics. Dimers and fusion proteins are also disclosed as insulin and IGF-I receptor modulators.

US 2000-196018P	P 20000407
US 2001-259548P	P 20010103
AU 2000-37360	A3 20000309
WO 2001-US7160	W 20010305

=> d hitrn

L60 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

IT **360804-23-5**

RL: BSU (Biological study, unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; human FCTR proteins related to growth factors and
cDNAs encoding them and their use in drug screening and therapy)

44

=> d hitrn 51

L57 ANSWER 51 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT 275828-97-2

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequence; interleukin-3-regulated aldoketo reductase gene in myeloid cells in autocrine regulation of myelopoiesis)

=> d hitrn 55

L57 ANSWER 55 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT 220134-97-4 245673-98-7

RL: PRP (Properties)
(amino acid sequence; cDNA sequences, and expression regulation of human and mouse DCIR, C-type lectin surface receptor containing immunoreceptor tyrosine-based inhibitory motif, that is expressed by antigen-presenting cells)

=> d hitrn 60

L57 ANSWER 60 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT 212774-49-7P

RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(amino acid sequence; cloning and cDNA and deduced amino acid sequences of 28 human secreted proteins)

=> d hitrn 63

L57 ANSWER 63 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT 208768-96-1, Protein (human gene hph2)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; isolation and sequence and diagnostic and therapeutic use of human polyhomeotic 2 (hph2) gene and protein)

=> d hitrn 65

L57 ANSWER 65 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT 203211-65-8

RL: PRP (Properties)
(amino acid sequence; characterization and chromosomal localization of PTPRO, a novel receptor protein tyrosine phosphatase, expressed in hematopoietic stem cells)

=> d hitrn 67

L57 ANSWER 67 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT 194615-66-2

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, as presenilin-binding protein; genes for proteins)

L3: more than One

ANSWER 9 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~505104-76-7P 505104-78-9P 505104-79-0P~~

~~RL: BPN (Biosynthetic preparation); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)~~

~~(peptides from various peptide libraries, their dimers and fusion proteins as modulators of insulin and IGF-1 receptors)~~

=> d hitrn 15

L57 ANSWER 15 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~441408-43-1~~, Polyprotein (human adenovirus 11)

~~RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)~~

~~(amino acid sequence; adenovirus type 11 and 4 based-viral vector for gene therapy)~~

L15: really long

ELKIKNR

more than one

=> d hitrn 20

L57 ANSWER 20 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~404559-13-3~~

~~RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)~~

~~(amino acid sequence, as prostate cancer marker; screening of peptide libraries to identify highly specific ligands and cognate receptors for cell or tissue-specific targeting)~~

more than one on L4

=> d hitrn 21

L57 ANSWER 21 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~403561-79-5~~

~~RL: PRP (Properties)~~

~~(unclaimed protein sequence; new members of the four-disulfide-core family of proteinase inhibitors identified by sequence homol. and cDNAs encoding them and their uses)~~

L19

more than one

=> d hitrn 29

L57 ANSWER 29 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~372032-61-6 372032-98-9 372035-37-5~~

~~372035-92-2 372036-31-2 372037-96-2~~

~~372038-45-4 372038-55-6 372038-64-7~~

~~372039-55-9 372039-71-9 372040-47-6~~

~~372041-34-4 372043-19-1 372044-44-5~~

~~372045-45-9 372046-48-5 372046-73-6~~

~~372047-29-5 372052-15-8 372052-75-0~~

~~372053-99-1 372056-50-3 372058-05-4~~

~~372058-89-4 372060-52-1 372060-72-5~~

~~372062-39-0 372064-72-7 372065-11-7~~

~~372065-92-4 372067-08-4 372067-95-3~~

~~372068-15-0 372068-73-0 372070-81-0~~

~~372071-05-1 372071-07-3 372071-11-9~~

~~372071-90-4 372071-93-9 372072-30-5~~

~~372072-78-1 372073-21-7 372488-87-4~~

~~RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)~~

~~(amino acid sequence; complete genome sequence of a multiple drug resistant Salmonella enterica serovar typhi CT18)~~

=> d hitrn 36

L3

more than one

L57 ANSWER 36 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT **357361-72-9**

RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence);
BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological
study); OCCU (Occurrence)

(amino acid sequence; cDNA sequence of human PRAM-1, novel adaptor
protein regulated by retinoate (RA) and PML-RA receptor α in
acute promyelocytic leukemia cells)

=> d hitrn 37

L57 ANSWER 37 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT **339609-69-7 339609-72-2**, 1-132-Antigen KLIP-1 (human
clone 36-16) **339609-79-9**, 1-129-Antigen KLIP-1 (mouse)
339609-80-2, Antigen KLIP-1 (human clone 36-16)

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP
(Properties); THU (Therapeutic use); BIOL (Biological study); OCCU
(Occurrence); USES (Uses)

(amino acid sequence; surface protein of hematopoietic stem cells of
lymphoid line and of NK cells, cDNA encoding it and its uses)

IT **339614-25-4 339614-26-5**

RL: PRP (Properties)

(unclaimed protein sequence; surface protein of hematopoietic stem
cells of the lymphoid line and of NK cells, a cDNA encoding it and its
uses)

=> d hitrn 39

L21

more than one

L57 ANSWER 39 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT **358804-92-9**, Immunoglobulin receptor LLIR (human)

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
(Properties); BIOL (Biological study); PROC (Process)

(amino acid sequence; cloning and characterization of a novel ITIM
containing lectin-like immunoreceptor LLIR and its two transmembrane region
deletion variants)

=> d hitrn 42

L3

L57 ANSWER 42 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT **310907-27-8**, Cytokine C121 (human kidney)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(amino acid sequence; cloning of cDNA for novel cytokine C121 from mice
and human)

more than one

=> d hitrn 43

L6

L57 ANSWER 43 OF 78 HCAPLUS COPYRIGHT 2006 ACS on STN

IT **294682-28-3**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(amino acid sequence; interleukin 21 and interleukin 21 receptor cDNA
sequences from mouse and human and role in natural killer cell
expansion in bone marrow and regulation of lymphocyte
function)

more than one

that interact with presenilins and their role in familial Alzheimer's disease and therapeutic use)

=> s 157 and Vernet/au
1 VERNET/AU
L58 0 L57 AND VERNET/AU

=> s 157 and Vernet/in
0 VERNET/IN
L59 0 L57 AND VERNET/IN

=> s 157 and FCTR/ti
3 FCTR/TI
L60 1 L57 AND FCTR/TI

=> d ibib

L60 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:676947 HCAPLUS

DOCUMENT NUMBER: 135:237112

TITLE: Human **FCTR** proteins related to growth factors and cDNAs encoding them and their use in drug screening and therapy

INVENTOR(S): Vernet, Corine A. M.; Fernandes, Elma; Shimkets, Richard A.; Herrmann, John L.; Majumder, Kumud; MacDougall, John; Mishra, Vishnu; Mezes, Peter S.; Rastelli, Luca

PATENT ASSIGNEE(S): Curagen Corporation, USA

SOURCE: PCT Int. Appl., 215 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 165

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066747	A2	20010913	WO 2001-US7160	20010305 <--
WO 2001066747	A3	20020718		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2401552	AA	20010915	CA 2001-2401552	20010305 <--
EP 1261712	A2	20021204	EP 2001-920218	20010305 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003087816	A1	20030508	US 2001-800198	20010305 <--
JP 2003525634	T2	20030902	JP 2001-565901	20010305 <--
US 2002155115	A1	20021024	US 2001-808602	20010314 <--
AU 2005200106	A1	20050210	AU 2005-200106	20050112
PRIORITY APPLN. INFO.:			US 2000-186592P	P 20000303
			US 2000-186718P	P 20000303
			US 2000-187718P	P 20000303
			US 2000-187293P	P 20000306
			US 2000-187294P	P 20000306
			US 2000-190400P	P 20000317